



Press Release

Wednesday, 18 March 2009

Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE: 532531

NSE : STAR

Strides Receives USFDA Inspection Approval Status for its Steriles Injectable Complex “Zero 483’s Status”

Strides Arcolab is pleased to announce that the USFDA, post a GMP & pre-approval inspection approved the Company’s Sterile Complex at Bilekahalli, Bangalore to be cGMP compliant.

- ✓ No 483 observations were issued during the inspection.
- ✓ In 2008, the Penicillin Block was also approved without any 483 observations.
- ✓ The company’s Sterile complex has three dedicated blocks manufacturing :
 - Penicillin
 - Cephalosporin
 - Injectables in Dry Powder, Liquid Vials, Prefilled Syringes and Lyophilised product.
- ✓ Strides has 14 sterile approvals from the FDA and 51 ANDA application pending with the agency.
- ✓ 4 new Sterile complexes are expected to be inspected in 2009.
 - For Oncology (Anticancer)
 - A new complex for Sterile injectables (in Bangalore)
 - A controlled substances facility in Poland and
 - Penem facility in Campos, Brazil (JV with Aspen)
- ✓ Strides recently completed a Rs.3500 mio expansion in Steriles expanding its capacity by over 500%.

In a statement issued on this occasion Venkat Iyer, CEO – India Operations said, “A Zero 483 approval for compliance in a challenging manufacturing and regulatory environment the Pharma industry is currently facing is indeed a landmark”.

With over 100 sterile products (including filing guidance of 40 in 2009) and strong manufacturing investments completed we are confident of emerging as a Global player in this niche segment.

Strides Overview

Strides, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a Bangalore, India head quartered global pharmaceutical company. Strides manufactures pharmaceutical formulations in various dosage forms including sterile injectables with dedicated facilities for Penicillin and Penams, Cephalosporins, Oncolytics and lyophilized injectable products. The company also manufactures pharmaceutical formulations in oral dosage forms, including capsules & tablets and Softgel capsules. Strides operates in and has significant presence in Australasia, Africa and India and through a series of strategies is expanding its North American and European growth. The company has series of joint ventures and front-ended operations in major markets and is a majority stakeholder of Ascent Pharmahealth Limited (APH), an ASX listed company. The company also collaborates closely with Global Drug Agencies and US PEPFAR and the UNICEF to supply a range of affordable generic pharmaceutical products used in the treatment of HIV, TB and Malaria.

Strides has manufacturing facilities in Bangalore, India and overseas facilities in Milan, Warsaw, Singapore and Lagos. The Indian manufacturing facilities are approved by all major regulatory bodies. Strides employs approximately 2,500 people across the globe. Strides also has a marketing presence in over 50 countries.

Additional information is available at the company’s website at www.stridesarco.com

For further information, please contact

Mr. Arun Kumar, Group CEO Tel: +91-80-6658 0118	Mahesh Nair, Corporate Voice/ Weber Shandwick Mobile : +91 98803 76648 Email: maheshn@corvoshandwick.co.in
Mr.Venkat Iyer, CEO - India Operations Tel: +91 80 6658 0110	Kasturi Wasmatar, Corporate Voice/ Weber Shandwick Mobile: +91 99167 28393 Email: kasturi@corvoshandwick.co.in